CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 133,606	$ 132,660	$ 401,818	$ 350,413	$ 494,366
Cost of revenues	30,206	28,395	85,190	78,365	106,501
Gross profit	103,400	104,265	316,628	272,048	387,865
Operating costs and expenses:
Research, development and clinical trials	48,141	32,818	144,372	88,008	132,010
Sales and marketing	32,580	29,364	98,075	86,658	118,017
General and administrative	31,231	27,061	95,116	79,073	107,437
Total operating costs and expenses	111,952	89,243	337,563	253,739	357,464
Operating income (loss)	(8,552)	15,022	(20,935)	18,309	30,401
Financial expenses (income), net	1,981	3,983	5,567	9,032	12,299
Income (loss) before income tax	(10,533)	11,039	(26,502)	9,277	18,102
Income tax	2,591	1,755	5,391	(5,614)	(1,706)
Net income (loss)	$ (13,124)	$ 9,284	$ (31,893)	$ 14,891	$ 19,808
Basic net income (loss) per ordinary share (in usd per share)	$ (0.13)	$ 0.09	$ (0.31)	$ 0.15	$ 0.20
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	103,731,147	101,234,306	103,281,380	100,601,427	100,930,866
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.13)	$ 0.09	$ (0.31)	$ 0.14	$ 0.18
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	103,731,147	108,643,814	103,281,380	108,113,416	108,877,648